SEC Form S-8 POS filed by CalciMedica Inc.
As filed with the Securities and Exchange Commission on June 27, 2025
Registration No. 333-288287
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1
TO
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
CalciMedica, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 45-2120079 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
505 Coast Boulevard South, Suite 307 La Jolla, California |
92037 | |
(Address of Principal Executive Offices) | (Zip Code) |
2023 Equity Incentive Plan
2023 Employee Stock Purchase Plan
(Full titles of the plans)
A. Rachel Leheny, Ph.D.
Chief Executive Officer
505 Coast Boulevard South, Suite 307
La Jolla, California 92037
(858) 952-5500
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Thomas A. Coll Carlos Ramirez Cooley LLP 10265 Science Center Drive San Diego, California 92121 |
John M. Dunn General Counsel 505 Coast Boulevard South, Suite 307 La Jolla, California 92037 | |
(858) 550-6000 | (858) 952-5500 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 (Registration No. 333-288287) previously filed with the SEC on June 24, 2025 (the “Registration Statement”) is being filed solely for the purpose of filing Exhibit 23.3 thereto, which was inadvertently omitted when the Registration Statement was filed. All other portions of the Registration Statement, as previously filed, remain unchanged.
PART I
ITEM 8. EXHIBITS.
* | Filed herewith. |
** | Previously filed. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of La Jolla, State of California, on June 27, 2025.
CALCIMEDICA, INC. | ||
By: | /s/ A. Rachel Leheny, Ph.D. | |
A. Rachel Leheny, Ph.D. | ||
Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No. 1 to the Registration Statement on Form S-8, has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date | ||
/S/ A. RACHEL LEHENY, PH.D. A. Rachel Leheny, Ph.D. |
Chief Executive Officer and Director (Principal Executive Officer) |
June 27, 2025 | ||
/S/ STEPHEN BARDIN Stephen Bardin |
Chief Financial Officer (Principal Financial and Accounting Officer) |
June 27, 2025 | ||
* Robert N. Wilson |
Chairman | June 27, 2025 | ||
* Alan Glicklich |
Director | June 27, 2025 | ||
* Frederic Guerard, Pharm.D. |
Director | June 27, 2025 | ||
* Fred Middleton |
Director | June 27, 2025 | ||
* Eric W. Roberts |
Director | June 27, 2025 | ||
* Allan Shaw |
Director | June 27, 2025 |
*By: | /s/ A. RACHEL LEHENY, PH.D. | |
A. Rachel Leheny, Ph.D. | ||
Attorney-in-Fact |